Payment overview · 2025
General Payments
$261.14
15 reported records · 5 companies
Healthcare provider profile · identity verified
Farrukh Anwar, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CARO, MI · NPI 1144268947
Verified facts
What the public records show
CMS Open Payments records show Farrukh Anwar, MD received $261.14 in general payments during 2025 across 15 reported records.
ABBVIE INC. accounted for 65.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENBREL as an associated drug or biological on 9330 records involving 2094 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Enbrel by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Nuedexta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $170.54 | 65.3% | 10 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $30.55 | 11.7% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $27.52 | 10.5% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.74 | 6.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.79 | 6.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $233.62 | 13 |
| Education | $27.52 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $118.77 | 7 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $51.77 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $30.55 | 1 | 2025 |
Source payment records
|
|||||
| EOHILIA Normalized: eohilia |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $27.52 | 2 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $16.74 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.79 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | ENBREL open payments reported associated product |
CMS Open Payments — General Payments 9330 supporting records · 2094 recipient NPIs · example record 1226877474 |
Enbrel · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
51 | 15 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 774 | 173 |
| Atorvastatin Calcium | Atorvastatin Calcium | 707 | 151 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 598 | 130 |
| Potassium Chloride | Potassium Chloride | 496 | 111 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 478 | 124 |
| Amlodipine Besylate | Amlodipine Besylate | 388 | 98 |
| Losartan Potassium | Losartan Potassium | 379 | 113 |
| Liothyronine Sodium | Liothyronine Sodium | 338 | 77 |
| Bumetanide | Bumetanide | 334 | 71 |
| Gabapentin | Gabapentin | 327 | 87 |
| Eliquis | Apixaban | 320 | 57 |
| Carvedilol | Carvedilol | 297 | 84 |
| Sertraline Hcl | Sertraline Hcl | 286 | 84 |
| Omeprazole | Omeprazole | 285 | 80 |
| Memantine Hcl | Memantine Hcl | 282 | 50 |
| Ropinirole Hcl | Ropinirole Hcl | 279 | 73 |
| Tamsulosin Hcl | Tamsulosin Hcl | 261 | 62 |
| Metoprolol Tartrate | Metoprolol Tartrate | 249 | 59 |
| Pantoprazole Sodium | Pantoprazole Sodium | 229 | 61 |
| Prednisone | Prednisone | 191 | 84 |
| Clopidogrel | Clopidogrel Bisulfate | 177 | 42 |
| Metformin Hcl | Metformin Hcl | 176 | 50 |
| Methotrexate | Methotrexate Sodium | 167 | 54 |
| Citalopram Hbr | Citalopram Hydrobromide | 161 | 34 |
| Donepezil Hcl | Donepezil Hcl | 151 | 39 |
| Lisinopril | Lisinopril | 150 | 36 |
| Metolazone | Metolazone | 142 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 141 | 35 |
| Jardiance | Empagliflozin | 139 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 136 | 30 |
| Pregabalin | Pregabalin | 135 | 24 |
| Furosemide | Furosemide | 134 | 49 |
| Allopurinol | Allopurinol | 129 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 128 | 32 |
| Januvia | Sitagliptin Phosphate | 125 | 19 |
| Alprazolam | Alprazolam | 122 | 44 |
| Trazodone Hcl | Trazodone Hcl | 120 | 33 |
| Tramadol Hcl | Tramadol Hcl | 118 | 46 |
| Levetiracetam | Levetiracetam | 117 | 17 |
| Cephalexin | Cephalexin | 116 | 84 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 116 | 25 |
| Alendronate Sodium | Alendronate Sodium | 114 | 37 |
| Spironolactone | Spironolactone | 107 | 23 |
| Bethanechol Chloride | Bethanechol Chloride | 94 | 18 |
| Famotidine | Famotidine | 93 | 34 |
| Aripiprazole | Aripiprazole | 89 | 19 |
| Risperidone | Risperidone | 89 | 19 |
| Myrbetriq | Mirabegron | 87 | 15 |
| Mirtazapine | Mirtazapine | 86 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 86 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 81 | 27 |
| Glipizide | Glipizide | 81 | 28 |
| Trulicity | Dulaglutide | 81 | 13 |
| Ezetimibe | Ezetimibe | 80 | 18 |
| Olanzapine | Olanzapine | 80 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 80 | 16 |
| Methylprednisolone | Methylprednisolone | 78 | 69 |
| Latanoprost | Latanoprost | 73 | 12 |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 73 | 26 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 72 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 71 | 29 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 68 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 68 | 11 |
| Azithromycin | Azithromycin | 67 | 49 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 66 | 29 |
| Buspirone Hcl | Buspirone Hcl | 65 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 65 | 12 |
| Warfarin Sodium | Warfarin Sodium | 63 | suppressed |
| Xarelto | Rivaroxaban | 61 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 60 | 12 |
| Montelukast Sodium | Montelukast Sodium | 59 | 14 |
| Simvastatin | Simvastatin | 59 | 12 |
| Fenofibrate | Fenofibrate,micronized | 58 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 57 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 57 | 25 |
| Sulfasalazine | Sulfasalazine | 57 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 56 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 55 | 17 |
| Baclofen | Baclofen | 53 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 53 | 15 |
| Nystatin | Nystatin | 53 | 26 |
| Finasteride | Finasteride | 52 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | 17 |
| Clobetasol Propionate | Clobetasol Propionate | 51 | 25 |
| Ozempic | Semaglutide | 51 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 50 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 50 | 12 |
| Ibandronate Sodium | Ibandronate Sodium | 48 | 25 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 48 | 14 |
| Sucralfate | Sucralfate | 48 | 14 |
| Topiramate | Topiramate | 48 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 46 | 32 |
| Entresto | Sacubitril/Valsartan | 46 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 44 | 15 |
| Enbrel Sureclick | Etanercept | 43 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 43 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 42 | suppressed |
| Celecoxib | Celecoxib | 42 | 12 |
| Divalproex Sodium | Divalproex Sodium | 39 | suppressed |
| Lorazepam | Lorazepam | 39 | 16 |
| Labetalol Hcl | Labetalol Hcl | 38 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 38 | suppressed |
| Novolog Flexpen | Insulin Aspart | 36 | 14 |
| Bupropion Xl | Bupropion Hcl | 35 | suppressed |
| Lamotrigine | Lamotrigine | 35 | suppressed |
| Sulindac | Sulindac | 35 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 30 |
| Enbrel | Etanercept | 34 | suppressed |
| Glipizide Er | Glipizide | 34 | 11 |
| Metronidazole | Metronidazole | 34 | 19 |
| Sulfasalazine Dr | Sulfasalazine | 34 | 17 |
| Propranolol Hcl | Propranolol Hcl | 33 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 31 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 21 |
| Clonazepam | Clonazepam | 30 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 30 | 14 |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 28 | suppressed |
| Fentanyl | Fentanyl | 28 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 28 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 27 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 27 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 26 | 13 |
| Levofloxacin | Levofloxacin | 26 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 26 | suppressed |
| Niacin Er | Niacin | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Meloxicam | Meloxicam | 25 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Humira(Cf) Pen | Adalimumab | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | 18 |
| Primidone | Primidone | 24 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 24 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | 13 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Clonidine | Clonidine | 21 | suppressed |
| Colchicine | Colchicine | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | 11 |
| Trospium Chloride | Trospium Chloride | 21 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Folic Acid | Folic Acid | 20 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 20 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Enulose | Lactulose | 19 | suppressed |
| Humira Pen | Adalimumab | 19 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 19 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 19 | suppressed |
| Novolin R | Insulin Regular, Human | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 18 | 18 |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 17 | 12 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 11 |
| Arnuity Ellipta | Fluticasone Furoate | 16 | suppressed |
| Cimzia (2 Pack) | Certolizumab Pegol | 16 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 16 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 15 | suppressed |
| Zonisamide | Zonisamide | 15 | suppressed |
| Cholestyramine Light | Cholestyramine | 14 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Cyclosporine | Cyclosporine | 13 | suppressed |
| Dalfampridine Er | Dalfampridine | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Indapamide | Indapamide | 13 | suppressed |
| Levetiracetam Er | Levetiracetam | 13 | suppressed |
| Multaq | Dronedarone Hcl | 13 | suppressed |
| Novolog | Insulin Aspart | 13 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Tetracycline Hcl | Tetracycline Hcl | 13 | suppressed |
| Timolol Maleate | Timolol Maleate | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Briviact | Brivaracetam | 11 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 11 | suppressed |
| Mesalamine | Mesalamine | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $261.14 · 15 records | ABBVIE INC. | EOHILIA, REXULTI, RINVOQ, SKYRIZI, TAVNEOS, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error